Skip to main navigation Skip to search Skip to main content

A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma

Research output: Contribution to journal › Editorial

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalKorean Journal of Internal Medicine
Volume41
Issue number2
DOIs
StatePublished - 2026.03

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Quacquarelli Symonds(QS) Subject Topics

  • Medicine

Cite this